Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Complement and coagulation cascades | R-HSA-114591 | map04610 | tanespimycin | 6505803 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | tomelukast | 3969 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | tomelukast | 3969 | drug-path |
| Phosphatidylinositol signaling system | R-HSA-1280215 | map04070 | raloxifene | 5035 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | raloxifene | 5035 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | raloxifene | 5035 | drug-path |
| Thyroid cancer | R-HSA-9700206 | map05216 | raloxifene | 5035 | drug-path |
| RNA polymerase | R-HSA-73864 | map03020 | raloxifene | 5035 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | nordihydroguaiaretic acid | 441145 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | nordihydroguaiaretic acid | 441145 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | nordihydroguaiaretic acid | 441145 | drug-path |
| MAPK signaling pathway | R-HSA-9652817 | map04010 | nordihydroguaiaretic acid | 441145 | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | nordihydroguaiaretic acid | 441145 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | sulfasalazine | 73160 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | sulfasalazine | 73160 | drug-path |
| Natural killer cell mediated cytotoxicity | R-HSA-5218921 | map04650 | sulfasalazine | 73160 | drug-path |
| Calcium signaling pathway | R-HSA-381753 | map04020 | sulfasalazine | 73160 | drug-path |
| Ubiquitin mediated proteolysis | R-HSA-983153 | map04120 | celecoxib | 2662 | drug-path |
| Alzheimer's disease | R-HSA-1643685 | 0 | celecoxib | 2662 | drug-path |
| Insulin signaling pathway | R-HSA-74752 | map04910 | celecoxib | 2662 | drug-path |